Compare RYAM & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | TMCI |
|---|---|---|
| Founded | 1926 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.7M | 401.8M |
| IPO Year | N/A | 2021 |
| Metric | RYAM | TMCI |
|---|---|---|
| Price | $6.30 | $2.74 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $7.07 |
| AVG Volume (30 Days) | 455.8K | ★ 1.3M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,471,356,000.00 | $218,879,000.00 |
| Revenue This Year | N/A | $3.25 |
| Revenue Next Year | $6.99 | $1.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.90 |
| 52 Week Low | $3.35 | $2.56 |
| 52 Week High | $8.65 | $10.79 |
| Indicator | RYAM | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 24.19 |
| Support Level | $6.31 | $2.64 |
| Resistance Level | $6.58 | $3.15 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 77.73 | 31.83 |
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.